Cargando…

Attenuation of Rheumatoid Arthritis Through the Inhibition of Tumor Necrosis Factor–Induced Caspase 3/Gasdermin E–Mediated Pyroptosis

OBJECTIVE: To determine the role of gasdermin E (GSDME)–mediated pyroptosis in the pathogenesis and progression of rheumatoid arthritis (RA), and to explore the potential of GSDME as a therapeutic target in RA. METHODS: The expression and activation of caspase 3 and GSDME in the synovium, macrophage...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhai, Zeqing, Yang, Fangyuan, Xu, Wenchao, Han, Jiaochan, Luo, Guihu, Li, Yehao, Zhuang, Jian, Jie, Hongyu, Li, Xing, Shi, Xingliang, Han, Xinai, Luo, Xiaoqing, Song, Rui, Chen, Yonghong, Liang, Jianheng, Wu, Shufan, He, Yi, Sun, Erwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2022
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305212/ https://www.ncbi.nlm.nih.gov/pubmed/34480835 http://dx.doi.org/10.1002/art.41963

Ejemplares similares

Blocking GSDME-mediated pyroptosis in renal tubular epithelial cells alleviates disease activity in lupus mice
por: Luo, Guihu, et al.
Publicado: (2022)

Disulfiram alleviates pristane-induced lupus via inhibiting GSDMD-mediated pyroptosis
por: Zhuang, Lili, et al.
Publicado: (2022)

Characterization and Function of Tumor Necrosis Factor and Interleukin‐6–Induced Osteoclasts in Rheumatoid Arthritis
por: Yokota, Kazuhiro, et al.
Publicado: (2021)

Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
por: Low, Audrey S. L., et al.
Publicado: (2016)

Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2012)

Metabolic Profiling Predicts Response to Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis
por: Kapoor, Sabrina R, et al.
Publicado: (2013)

Replication of Association of the PTPRC Gene With Response to Anti–Tumor Necrosis Factor Therapy in a Large UK Cohort
por: Plant, Darren, et al.
Publicado: (2012)

Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis
por: Nurmohamed, Michael, et al.
Publicado: (2015)

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
por: Weitz, Jeffrey I, et al.
Publicado: (2022)

Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis
por: Sauer, Brian C., et al.
Publicado: (2017)

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
por: Strand, Vibeke, et al.
Publicado: (2017)

Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients’ offspring
por: Smeele, Hieronymus T W, et al.
Publicado: (2022)

Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study
por: Calabrese, Leonard H., et al.
Publicado: (2020)

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study
por: Kim, Seoyoung C., et al.
Publicado: (2017)

Treatment of Rheumatoid Arthritis With Anti–Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study
por: Choy, Ernest H., et al.
Publicado: (2017)

Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
por: Fleischmann, Roy, et al.
Publicado: (2017)

Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis
por: Virone, Alexandre, et al.
Publicado: (2019)

Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland
por: Finckh, A, et al.
Publicado: (2020)

Phase II/III Results of a Trial of Anti–Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2022)

No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
por: Lunt, Mark, et al.
Publicado: (2010)

Genome-Wide Association Study of Genetic Predictors of Anti–Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations with Polymorphisms at Seven Loci
por: Plant, Darren, et al.
Publicado: (2011)

Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis
por: Jani, Meghna, et al.
Publicado: (2015)

Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial
por: Balanescu, Andra-Rodica, et al.
Publicado: (2022)

A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy
por: Kremer, Joel M., et al.
Publicado: (2016)

Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib,
por: Charles‐Schoeman, Christina, et al.
Publicado: (2015)

Novel insight into the aetiology of rheumatoid arthritis gained by a cross-tissue transcriptome-wide association study
por: Ni, Jing, et al.
Publicado: (2022)

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
por: Lillegraven, Siri, et al.
Publicado: (2023)

The mechanisms of hydroxychloroquine in rheumatoid arthritis treatment: Inhibition of dendritic cell functions via Toll like receptor 9 signaling
por: Han, Jiaochan, et al.
Publicado: (2020)

Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week‐112 Efficacy and Safety Results of the Open‐Label Long‐Term Extension of a Phase III, Double‐Blind, Randomized, Placebo‐Controlled Trial
por: Bingham, Clifton O., et al.
Publicado: (2015)

Stage-specific roles of microbial dysbiosis and metabolic disorders in rheumatoid arthritis
por: Cheng, Mingyue, et al.
Publicado: (2022)

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
por: Emamikia, Sharzad, et al.
Publicado: (2016)

CD109 regulates the inflammatory response and is required for the pathogenesis of rheumatoid arthritis
por: Song, Guanhua, et al.
Publicado: (2019)

ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double‐Blind Study
por: Genovese, Mark C., et al.
Publicado: (2018)

Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses
por: Choy, Ernest, et al.
Publicado: (2019)

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
por: Feist, Eugen, et al.
Publicado: (2022)

Age affects joint space narrowing in patients with early active rheumatoid arthritis
por: Matthijssen, X M E, et al.
Publicado: (2016)

PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes
por: Tu, Jiajie, et al.
Publicado: (2023)

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2016)

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
por: Winthrop, Kevin L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s6heamsdmafhc0c068us3ljjck